{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:34:40Z","timestamp":1794656080408,"version":"4.9.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinthera.2025.05.011","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:21:43Z","timestamp":1750432903000},"page":"1016-1023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Indirect Comparison of Maralixibat and Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis"],"prefix":"10.1016","volume":"47","author":[{"given":"Guy","family":"Lacey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Gosden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Darlington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Quadrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.05.011_bib0001","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cld.2022.03.003","article-title":"Overview of progressive familial intrahepatic cholestasis","volume":"26","author":"Hassan","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jceh.2013.10.005","article-title":"Progressive familial intrahepatic cholestasis","volume":"4","author":"Srivastava","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0003","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clinre.2018.07.010","article-title":"Systematic review of progressive familial intrahepatic cholestasis","volume":"43","author":"Baker","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0004","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4254\/wjh.v14.i1.98","article-title":"Recent updates on progressive familial intrahepatic cholestasis types 1, 2 and 3: outcome and therapeutic strategies","volume":"14","author":"Alam","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0005","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2010.01.034","article-title":"Differences in presentation and progression between severe FIC1 and BSEP deficiencies","volume":"53","author":"Pawlikowska","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0006","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/HMER.S137209","article-title":"Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment","volume":"10","author":"Gunaydin","year":"2018","journal-title":"Hepat Med"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0007","article-title":"Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis","volume":"6","author":"McKiernan","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0008","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/liv.14553","article-title":"Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis","volume":"40","author":"Kamath","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0009","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S2468-1253(24)00080-3","article-title":"Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Miethke","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0010","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0011","article-title":"Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis","volume":"5","author":"Thompson","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0012","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1007\/s12325-022-02261-8","article-title":"Development of the patient-and observer-reported PRUCISION instruments to assess pruritus and sleep disturbance in pediatric patients with cholestatic liver diseases","volume":"39","author":"Gwaltney","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0013","unstructured":"PmtbZ MNumZ. Company Submission to G-BA for Benefit Assessment. Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Albireo AB, Odevixibat (Bylvay\u00ae). Modul 4 A2021."},{"key":"10.1016\/j.clinthera.2025.05.011_bib0014","unstructured":"Albireo. Statistical analysis plan (SAP). A double-blind, randomized, placebo-controlled, phase 3 study to demonstrate efficacy and safety of A4250 in children with progressive familial intrahepatic cholestasis types 1 and 2 (PEDFIC 1). Verision 6Aug 2019."},{"key":"10.1016\/j.clinthera.2025.05.011_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v011.i10","article-title":"Econometric computing with HC and HAC covariance matrix estimators","volume":"11","author":"Zeileis","year":"2004","journal-title":"J Stat Software"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v095.i01","article-title":"Various versatile variances: an object-oriented implementation of clustered covariances in R","volume":"95","author":"Zeileis","year":"2020","journal-title":"J Stat Software"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0017","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0018","series-title":"Indirect evidence: indirect treatment comparisons in meta-analysis","author":"Wells","year":"2009"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0019","unstructured":"Ipsen Pharma. Bylvay summary of product characteristics. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bylvay-epar-product-information_en.pdf. Revised June 6, 2025. Accessed June 13, 2025."},{"key":"10.1016\/j.clinthera.2025.05.011_bib0020","unstructured":"Ipsen Biopharmaceuticals, Inc. Bylvay prescribing information. US Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215498s006lbl.pdf. Revised March 2025. Accessed June 13, 2025."},{"key":"10.1016\/j.clinthera.2025.05.011_bib0021","unstructured":"Mirum Pharmaceuticals, Inc. Livmarli prescribing information. US Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219485s000lbl.pdf. Revised April 2025. Accessed June 13, 2025."},{"key":"10.1016\/j.clinthera.2025.05.011_bib0022","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31787","article-title":"Impact of genotype, serum bile acids, and surgical biliary diversion on native liver survival in FIC1 deficiency","volume":"74","author":"van Wessel","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2025.05.011_bib0023","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2020.02.007","article-title":"Genotype correlates with the natural history of severe bile salt export pump deficiency","volume":"73","author":"van Wessel","year":"2020","journal-title":"J Hepatol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:55:34Z","timestamp":1774947334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825001754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0149291825001754"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.05.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indirect Comparison of Maralixibat and Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}